<DOC>
	<DOCNO>NCT00291330</DOCNO>
	<brief_summary>The purpose trial determine comparative safety efficacy dabigatran etexilate 150 mg bid administer orally warfarin need ( pro nata - prn ) maintain International Normalised Ratio ( INR ) 2.0-3.0 6 month treatment acute symptomatic venous thromboembolism ( VTE ) , follow initial treatment ( 5-10 day ) parenteral anticoagulant approve indication . This trial aim demonstrate non-inferiority dabigatran compare warfarin patient acute symptomatic VTE . After achieve non-inferiority , trial also aim establish superiority ( mean hierarchical test ) dabigatran warfarin .</brief_summary>
	<brief_title>Efficacy Safety Dabigatran Compared Warfarin 6 Month Treatment Acute Symptomatic Venous Thromboembolism</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Inclusion criterion 1 . Acute deep vein thrombosis ( DVT ) leg involve proximal vein , and/or pulmonary embolism ( PE ) iin patient least 6 month anticoagulant therapy consider appropriate 2 . Male female , 18 year age old 3 . Written inform consent study participation Exclusion criteria 1 . Overt symptoms VTE longer 2 week prior enrolment 2 . PE satisfy least one follow criterion : Haemodynamic instability , embolectomy indicate perform , thrombolytic therapy indicate perform , suspect source PE legs 3 . Actual anticipate use vena cava filter 4 . Contraindications anticoagulant therapy 5 . Patients investigators opinion treat warfarin 6 . Allergy heparins alternate approve therapy use initial treatment , warfarin dabigatran , one excipients include medication 7 . Patients investigator judgement perceive excessive risk bleed 8 . Known anaemia 9 . Need anticoagulant treatment disorder VTE 10 . Recent unstable cardiovascular disease 11 . Elevated AST ALT &gt; 2x ULN 12 . Liver disease expect potential impact survival 13 . Patients develop transaminase elevation upon exposure ximelagatran 14 . Severe renal impairment 15 . Women pregnant , nursing , childbearing potential refuse use medically acceptable form contraception 16 . Participation another clinical trial investigational drug last 30 day previous participation study 17 . Patients consider unsuitable inclusion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>